PT-141 (Bremelanotide) Effect on CMP (Comprehensive Metabolic Panel)

What Is PT-141 (Bremelanotide) and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds primarily to MC3R and MC4R in the central nervous system to modulate sexual desire, making it mechanistically distinct from PDE5 inhibitors and hormonal therapies. The FDA approved it on June 21, 2019, under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women at a fixed subcutaneous dose of 1.75 mg, administered at least 45 minutes before anticipated sexual activity.

Off-label use in men for erectile dysfunction and low libido also occurs, though no phase 3 data in men has reached the level of the RECONNECT trials.

Mechanism Relevant to Lab Values

Understanding why bremelanotide is largely neutral on CMP values starts with its pharmacokinetics. After subcutaneous injection, bremelanotide reaches peak plasma concentration (Cmax) in approximately 1 hour and has a half-life of roughly 2.7 hours. It undergoes hydrolysis rather than hepatic CYP450 metabolism, which is the reason hepatotoxic potential is low compared with drugs that are extensively metabolized by CYP3A4 or CYP2C9. Renal excretion accounts for about 64.8% of the administered dose, but circulating concentrations are insufficient to cause tubular toxicity at approved doses.

What a CMP Tests

A comprehensive metabolic panel covers 14 analytes across three functional domains:

• Liver function: ALT, AST, alkaline phosphatase (ALP), total bilirubin, total protein, albumin
• Kidney function: BUN, creatinine, eGFR (calculated)
• Electrolytes and glucose: sodium, potassium, chloride, CO2 (bicarbonate), glucose, calcium

Each domain is discussed individually below in the context of what the clinical trial data and post-marketing surveillance actually show.

Does Bremelanotide Affect Liver Enzymes (ALT, AST, ALP, Bilirubin)?

The short answer is: modest, transient enzyme rises are possible, but they are not dose-limiting and they resolve without treatment in the data available. The pooled RECONNECT trials (N=1,267 premenopausal women) reported ALT or AST elevations above the upper limit of normal in a small subset of participants receiving bremelanotide 1.75 mg SC. None of those elevations met Hy's Law criteria (simultaneous aminotransferase elevation above 3x ULN plus bilirubin above 2x ULN), the threshold that signals serious drug-induced liver injury.

ALT and AST

ALT and AST are the two most monitored liver enzymes in any drug-safety program. In RECONNECT, the proportion of participants with treatment-emergent ALT or AST elevations was numerically higher in the bremelanotide arm than placebo, but the difference did not reach statistical significance, and no participant required dose interruption solely for hepatic laboratory findings. The mechanism behind these minor fluctuations is not fully defined; one hypothesis is that melanocortin receptor activation mildly modulates hepatic lipid handling, but no published pharmacology paper has confirmed this at therapeutic concentrations.

Alkaline Phosphatase

ALP was not called out as elevated in RECONNECT safety tables. Elevations in ALP typically indicate biliary obstruction or bone disease, neither of which has a plausible mechanistic link to melanocortin receptor agonism.

Total Bilirubin

Total bilirubin remained within normal limits across trial arms. No cases of jaundice were reported in the RECONNECT program or in FDA post-marketing adverse event summaries through the available surveillance window.

Clinical Takeaway for Liver Labs

Obtain a baseline CMP with liver function before the first injection. If a patient develops nausea, right upper quadrant discomfort, or jaundice while on bremelanotide, repeat liver function tests promptly. Routine serial monitoring of liver enzymes in asymptomatic patients is not mandated by the current FDA label, but clinical judgment should guide repeat testing in patients with pre-existing hepatic disease.

Does Bremelanotide Affect Kidney Function (BUN, Creatinine, eGFR)?

Bremelanotide does not appear to damage the kidneys at approved doses. BUN, serum creatinine, and calculated eGFR were stable across the treatment and placebo arms in the RECONNECT phase 3 program. Renal excretion is the primary elimination route, but the drug is excreted in its intact or hydrolyzed form, not as a nephrotoxic metabolite.

BUN and Creatinine

Neither BUN nor creatinine showed a statistically or clinically significant change from baseline in the RECONNECT data. The FDA prescribing information for Vyleesi does not list renal impairment monitoring as a routine requirement, though it does note that pharmacokinetic studies showed a roughly 1.5-fold increase in bremelanotide AUC in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), warranting caution in that population.

eGFR Considerations

For patients who already have chronic kidney disease (CKD) stages 3 to 5, a baseline CMP establishes eGFR before therapy starts. If creatinine rises unexpectedly during bremelanotide therapy, other causes (dehydration, concomitant NSAIDs, contrast exposure) should be evaluated before attributing the change to the drug. At present, no published case series documents bremelanotide-induced nephrotoxicity.

Practical Note on Dosing in Renal Impairment

The FDA label advises against use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to increased drug exposure, not because of direct kidney toxicity. Patients with moderate renal impairment (eGFR 30 to 59 mL/min/1.73 m²) may use bremelanotide but should have eGFR established at baseline and monitored periodically per the treating physician's discretion.

Does Bremelanotide Affect Electrolytes (Sodium, Potassium, Chloride, CO2)?

No electrolyte disturbances attributable to bremelanotide have been identified in clinical trials or post-marketing data. Sodium, potassium, chloride, and bicarbonate (CO2) were not flagged as abnormal in RECONNECT safety reporting. This is expected: melanocortin receptor signaling does not directly regulate renal sodium-potassium transporters or aldosterone secretion at the concentrations achieved with a 1.75 mg subcutaneous dose.

Sodium

Serum sodium was stable. Bremelanotide does cause transient nausea and vomiting in approximately 40% of users (the most common adverse effect reported in RECONNECT), which could theoretically predispose to mild hyponatremia from fluid shifts in patients who vomit repeatedly. In practice, this has not been documented as a laboratory-confirmed outcome.

Potassium

No hypokalemia or hyperkalemia signals have emerged from either the trial data or FDA's Adverse Event Reporting System (FAERS) database entries for bremelanotide. Potassium levels can shift with repeated vomiting (hypokalemia) as a secondary consequence of the drug's GI side effects, though again, published data documenting this specific complication in bremelanotide users do not exist as of the most recent literature review.

Clinical Takeaway for Electrolytes

Routine monitoring of electrolytes is not required by labeling. For patients who report frequent nausea and vomiting on bremelanotide, a follow-up CMP or basic metabolic panel to check potassium and bicarbonate is a reasonable clinical precaution.

Does Bremelanotide Affect Glucose or Calcium?

Glucose

Bremelanotide has no clinically meaningful effect on fasting glucose. The drug acts centrally on MC3R and MC4R for its intended sexual-desire effect and does not stimulate insulin secretion, inhibit glucagon, or alter hepatic glucose output at approved doses. Animal data suggest MC4R agonism can affect energy balance at very high doses, but translation to the 1.75 mg clinical dose in humans has not produced glucose changes in trial populations. Patients with type 2 diabetes do not need additional glucose monitoring beyond their usual diabetes management when starting bremelanotide.

Calcium

Total calcium was not identified as an analyte of concern in RECONNECT. Melanocortin receptors are expressed in some bone cell lines in animal models, but no clinical evidence supports an effect on serum calcium at the bremelanotide dose used therapeutically.

Total Protein and Albumin

Albumin and total protein remained stable in the RECONNECT cohort. Hypoalbuminemia can indicate liver disease, malnutrition, or nephrotic syndrome, none of which are associated with bremelanotide use. A low albumin on a baseline CMP before starting bremelanotide should prompt investigation of the underlying cause rather than being attributed to the drug.

RECONNECT Trials: What the Phase 3 Data Actually Show

The RECONNECT program consisted of two randomized, double-blind, placebo-controlled phase 3 trials. Combined, they enrolled 1,267 premenopausal women diagnosed with HSDD and assessed bremelanotide 1.75 mg SC versus placebo over a 24-week period. The primary results were published in Obstetrics and Gynecology in 2019.

Primary endpoints were the change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. Bremelanotide produced a statistically significant improvement in both measures versus placebo (P<0.001 for both co-primary endpoints across the pooled population).

Safety data from RECONNECT showed:

• Nausea: 40.0% bremelanotide vs. 1.2% placebo
• Flushing: 20.3% bremelanotide vs. 0.5% placebo
• Headache: 11.3% bremelanotide vs. 2.9% placebo
• Transient blood pressure increase (mean systolic +6 mmHg at 12 minutes post-dose): this is documented in labeling and is the most clinically significant acute physiologic change

On the question of laboratory values specifically, the RECONNECT safety tables did not list any CMP analyte as a treatment-emergent grade 3 or grade 4 laboratory abnormality requiring treatment discontinuation.

The FDA label, based on the RECONNECT data, carries a contraindication for patients with cardiovascular disease due to the transient blood pressure and heart rate elevation, but not a hepatic or renal contraindication beyond the severe renal impairment pharmacokinetic caution discussed above.

A Practical CMP Monitoring Framework for Bremelanotide Users

The absence of a labeling-mandated monitoring schedule does not mean no monitoring is warranted. The following framework reflects a synthesis of the FDA label, RECONNECT safety data, and standard telehealth prescribing practice for melanocortin-based therapies.

Before Starting Bremelanotide

Obtain a full CMP. This establishes:

1. Baseline liver enzyme values (ALT, AST, ALP, bilirubin) before any drug exposure
2. Baseline renal function (BUN, creatinine, eGFR) to identify patients with severe renal impairment who should not receive the drug
3. Baseline electrolytes and glucose to distinguish any future lab changes from pre-existing conditions

A blood pressure measurement at baseline is equally important given the transient pressor effect.

During Ongoing Bremelanotide Therapy

For patients using bremelanotide on an as-needed basis (the FDA-approved dosing pattern), the cumulative drug exposure is low compared with daily-dosed medications. No fixed repeat-CMP interval is required by labeling. A repeat CMP at 3 to 6 months is a reasonable choice for:

• Patients with pre-existing hepatic steatosis or elevated baseline enzymes
• Patients with stage 2 or 3 CKD at baseline
• Any patient who develops new right upper quadrant pain, jaundice, or unexplained fatigue

When to Stop and Investigate

Stop bremelanotide and obtain urgent liver function tests if:

• ALT or AST rises above 3x ULN on repeat testing
• Bilirubin rises concurrently with any transaminase elevation (potential Hy's Law signal)
• Patient reports persistent dark urine or jaundice

These are conservative thresholds borrowed from general drug-safety practice. No RECONNECT participant triggered this level of concern, but the threshold is clinically defensible.

Bremelanotide and Blood Pressure: The Lab-Adjacent Safety Issue

The CMP does not measure blood pressure, but any clinician ordering a CMP for a bremelanotide patient should note the drug's documented hemodynamic effect. A mean systolic increase of approximately 6 mmHg and a mean diastolic increase of approximately 3 mmHg occur within 12 minutes of injection and resolve within 12 hours in most users. The FDA label states: "Bremelanotide transiently increases blood pressure and decreases heart rate after each dose. Before prescribing Vyleesi, evaluate the patient's cardiovascular risk."

This hemodynamic effect does not alter CMP values directly, but it reinforces the case for a thorough baseline assessment that includes a metabolic panel alongside a blood pressure check.

How Bremelanotide Compares to Other Agents on CMP Impact

Physicians prescribing bremelanotide in a telehealth setting often manage patients who are also on testosterone replacement therapy, GLP-1 receptor agonists, or oral contraceptives. Understanding how CMP profiles interact matters.

Flibanserin (Addyi) Comparison

Flibanserin, the other FDA-approved agent for HSDD, is a CYP3A4 substrate and a weak CYP3A4 inhibitor. It carries a black-box warning for severe hypotension with alcohol and CYP3A4 inhibitors. Liver enzyme monitoring is advised with flibanserin in a way that is more rigorous than with bremelanotide, because flibanserin undergoes extensive hepatic metabolism. Bremelanotide's hydrolytic metabolism gives it a more favorable liver safety profile by comparison.

GLP-1 Receptor Agonists

GLP-1 agents such as semaglutide and tirzepatide can produce modest ALT reductions in patients with metabolic dysfunction-associated steatohepatitis (MASH), an effect attributed to fat-mass reduction. Patients on concurrent GLP-1 therapy and bremelanotide should not have CMP changes attributed to bremelanotide without first accounting for the GLP-1 contribution.

Testosterone (TRT/HRT)

Supraphysiologic testosterone can raise hematocrit and, in some studies, modestly raise AST (partly because AST is a muscle enzyme and testosterone promotes muscle protein synthesis). If a patient on TRT begins bremelanotide and shows a new AST elevation, concurrent TRT is a more likely explanation than bremelanotide.

Post-Marketing Safety Data on Bremelanotide and CMP

The FDA's FAERS database and post-marketing surveillance reports through 2024 do not identify a signal for drug-induced liver injury, acute kidney injury, or significant electrolyte disturbances attributable to bremelanotide. The FDA's drug label for Vyleesi includes nausea, flushing, injection site reactions, and transient blood pressure increases as the primary safety concerns. Laboratory abnormalities are not listed among the warnings and precautions.

This post-marketing absence of a CMP signal is meaningful. The as-needed dosing model limits cumulative hepatic and renal exposure compared with chronically dosed medications, and the hydrolytic rather than oxidative metabolism further limits reactive metabolite formation.

Special Populations and CMP Considerations

Patients with Pre-Existing Liver Disease

Bremelanotide pharmacokinetics in patients with hepatic impairment were studied in a dedicated PK trial. Mild hepatic impairment (Child-Pugh class A) did not meaningfully alter bremelanotide AUC. Moderate hepatic impairment (Child-Pugh class B) produced a modest increase in exposure; the label advises no dose adjustment, but clinical monitoring is prudent. Severe hepatic impairment (Child-Pugh class C) is not studied, and use should be avoided pending data.

Patients with Pre-Existing Renal Disease

As noted earlier, severe renal impairment (eGFR <30 mL/min/1.73 m²) increases bremelanotide AUC by approximately 1.5-fold. The FDA label recommends against use in this population. Patients with moderate CKD can proceed with careful monitoring.

Postmenopausal and Transgender Women

The FDA approval covers only premenopausal women, but off-label use in postmenopausal women and transgender women on hormone therapy is documented. No specific CMP data exist for these groups. A conservative approach applies standard baseline and symptomatic monitoring.

Practical Checklist for Prescribers

• Order a CMP before the first bremelanotide prescription.
• Document baseline blood pressure (systolic and diastolic) at the same visit.
• Confirm eGFR is above 30 mL/min/1.73 m² before proceeding.
• Review baseline ALT and AST; if either exceeds 2x ULN at baseline, investigate the cause before initiating therapy.
• Counsel the patient to report any yellow skin, dark urine, or persistent right-sided abdominal pain.
• Repeat CMP at 3 to 6 months for patients with pre-existing hepatic steatosis or CKD stage 2 to 3.
• For asymptomatic patients with normal baseline CMP and no renal or hepatic risk factors, no mandatory repeat interval exists per the FDA label.

The RECONNECT phase 3 data enrolled 1,267 participants and showed no CMP analyte reached grade 3 laboratory toxicity criteria in the bremelanotide arm, making routine intensive monitoring difficult to justify by the evidence. Still, a baseline CMP before the first dose remains the standard of care at HealthRX.